{"name":"FPR Specialty Pharmacy","slug":"fpr-specialty-pharmacy","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Diclofenac Cream 8%","genericName":"Diclofenac Cream 8%","slug":"diclofenac-cream-8","indication":"Topical treatment of localized pain and inflammation associated with osteoarthritis and other musculoskeletal conditions","status":"phase_3"}]}],"pipeline":[{"name":"Diclofenac Cream 8%","genericName":"Diclofenac Cream 8%","slug":"diclofenac-cream-8","phase":"phase_3","mechanism":"Diclofenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis, thereby decreasing inflammation and pain at the site of topical application.","indications":["Topical treatment of localized pain and inflammation associated with osteoarthritis and other musculoskeletal conditions","Acute pain relief from minor sprains, strains, and contusions"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9saVc3a0FoR3JhRy1YXzJsdkxtQmgwRkRSMUltcHQ1NWhibEo2VnJiV2k1WWNRcmd6dkpPV1U5S1diRV9zZnd1RHFkNVRzeVhkaC1KQ0JuTjg4S1hSRXpBT041QmNsWmMxU3Jxaml4WDZZLXBMd1VzczJUbXFtcUE?oc=5","date":"2026-01-12","type":"pipeline","source":"Pharmaceutical Executive","summary":"Operational Challenges for Specialty Pharmacies - Pharmaceutical Executive","headline":"Operational Challenges for Specialty Pharmacies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPaDNxTHUxTTBtRmxsWEJfTm44SnVUZ09GbnQ3QWlNZ0IzS1dlZUxhVGpIVVZvY3FLMjI5ZlltZDBqcGtfTS1JdTVhRkxwTmhZWVVLaUFtekZnVGZMUmxZMHVYM2RsQlFCbkc0Z1RMWGhqbHhkVzdwbFR0N01oZ0l4OA?oc=5","date":"2025-11-14","type":"pipeline","source":"MobiHealthNews","summary":"House Rx secures $55M for specialty pharmacy - MobiHealthNews","headline":"House Rx secures $55M for specialty pharmacy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1KMHRpRE84ZFBNM1lVc0pfOF9OSFZDMEZaMktULXVDbXpyUTlOb1I1bXZRNjdkZkJ0NzE3ZW1QR3hlSjc5dXNKcXl3SFpZZm94bHRkbUNHQzBxbHRjcmFPZHpPZldpblFQOV9aeW13ZVp1WkxuQ1AydWNmRQ?oc=5","date":"2025-11-10","type":"pipeline","source":"Advisory Board","summary":"The 3 trends reshaping the specialty drug pipeline today - Advisory Board","headline":"The 3 trends reshaping the specialty drug pipeline today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQTDllV2Y0eE1qX093QklLNFY0ajBVYTVWSjlxV0IwVlJDUVhwdmhIMHpyZDAtREFib0tCeXJ2OGhsUnN0d21jT285TW9MNV9qenE0NS1Kay1IX1RBbFEzeVgyemFlbkVOMC0zRWlaX2RBYzJWNHI4eGFSU3hQT1pqLTFRT3F5RnRodWJJZ1kxcW9PWDRGMWxGLWtsbXBuLW9XbmtoY3AySF9MbmhlT1pB?oc=5","date":"2025-10-14","type":"pipeline","source":"Fierce Healthcare","summary":"A new wave of middlemen offers 'alternative funding' for specialty drugs. Patients bear the risks - Fierce Healthcare","headline":"A new wave of middlemen offers 'alternative funding' for specialty drugs. Patients bear the risks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTE02cUVMb2FqZkg0aU5Tdm8xVW1nYU5RVW9FaVJDeVo5YVJXcS1XZFI1ak1hUWNxT2xoMUc2a2hmbzdSNkRYOXg2SzFMSmdZeGl3bjF0OEVmazlRVXROREJRdzJiZkFaY0k?oc=5","date":"2025-08-26","type":"pipeline","source":"antonhealth.com","summary":"Limited Distribution Updates - antonhealth.com","headline":"Limited Distribution Updates","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-22","type":"regulatory","source":"BioSpace","summary":"Cycle Pharmaceuticals Selects LeMed Specialty Pharmacy as Exclusive U.S. Specialty Pharmacy Distribution and Services Partner for HARLIKU™ (nitisinone) Tablets — the First and only FDA-approved Treatm","headline":"Cycle Pharmaceuticals Selects LeMed Specialty Pharmacy as Exclusive U.S. Specialty Pharmacy Distribution and Services Pa","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxQdFp5M015OUFjcFh3VDRiZnRMV0hha2ozMmVJVGd3UE5kSElPVFdpLVhKeV92bnMxQ2pzOXJJNV9lVVJtVk5EZjk0cUhieWIxMW5yNlVuS1JVb09SemF5cW1TLUpfbmVkcVZXYWRSa2w1VThjU1pJejlqb1J1OGZyd3BJTzRsYmFV?oc=5","date":"2025-03-11","type":"earnings","source":"Drug Channels","summary":"The Top 15 U.S. Pharmacies of 2024: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies - Drug Channels","headline":"The Top 15 U.S. Pharmacies of 2024: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPN2RCRXpaNzlwRjNKb3hIYjNKSW9ZM0N4S3UxQ3A3NUJGM0I4STFOcVgySU9rMW1ielZrR1RqZzZmTEQ2dFJjenhkN3lOXzZ4SEJ0SklVQm9IZm93d1R5NUxDQVloNGhHYXNKOFdpWGV4Zk12M3hubEZRMlJOR25VNzFlb05JX0lKODJIUDFseUY3Y3hDWFVjdXFnM2xJa0NJOExWRjdqNEtSTlVlcXlOYXE2MXlzV2JacmNJMEJJVjlpNUh3LUJaSVowVlBIMklVQ3E2azBkSFRITzZmYWRYTzc3a3BkQm43dll1dXp3?oc=5","date":"2024-08-08","type":"pipeline","source":"Deloitte","summary":"Growth of Specialty Lite May Create Challenges for Rx Stakeholders - Deloitte","headline":"Growth of Specialty Lite May Create Challenges for Rx Stakeholders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxORWFub1NCWDAyeEJBNHdfLS1iSjdKTnNIbk1FUFlLOGU4RVNweGdVTW9Sb3FfNXM3LVRVWThSMHVXMWRnb1VRSG94aGVlRWgxYVJKMUtocjJzc1VBV3lJemlod3lmUHFvRkRrWFB2ckJBTl9YZ29DRDlVQXlwX1hqT0pLdHh5czRlMHZidEZOM2ZhQ2RycUVCRk0zaTZGQjNjN3JfQ3hCZEZFUXNoZ3NXWE5lX1dTQXUxOWlnYXlRWnA?oc=5","date":"2024-04-25","type":"pipeline","source":"Specialty Pharmacy Continuum","summary":"The Dos and Don’ts of Enhanced Service Contracts - Specialty Pharmacy Continuum","headline":"The Dos and Don’ts of Enhanced Service Contracts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOUnVDMEhfNWV4WTFlbDk5Y1RVenZ4RDNsZndhT3huejdOWEMwYkJBeGl0ZEhBeHdwU2ZrT2hnMGhPUU5EaDMzb2dOTHFWU3h1bUl3UG9tOTUxaURYbmxWdG9mUlF6encyUWhWeE9MWHY0aXdOd2ZYbUVxMG5rWi14LW1ja1hFMWRO?oc=5","date":"2024-04-16","type":"earnings","source":"Drug Channels","summary":"The Top 15 Specialty Pharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents - Drug Channels","headline":"The Top 15 Specialty Pharmacies of 2023: Market Shares and Revenues at the Biggest PBMs, Health Plans, and Independents","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxQYUJlX1VVYzFTYWwtUHFWRUkyWmxmNWRaQk9JeDZFbmZoa295UHlwVEdHalFWVDdCMjk5RGNjRjBmdi1iaGRva2E5RUppTG1Hb29tcUM2SXNONFlvX2RXM0ZNMDJnWlRvNmdhSkUwel9RY3k1clVQNFQ4QTdsb0thZ2wtNDhyMWJ5TzNJUGJZdEdPNWNQUTJOUlFfX3lTNXBNR05hTGRJRHVhQ0NfWXVHb1FjVWZPNnlq?oc=5","date":"2021-06-10","type":"trial","source":"IQVIA","summary":"Five Data Disciplines for Specialty Product Manufacturers - IQVIA","headline":"Five Data Disciplines for Specialty Product Manufacturers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxORWswbm1NQk9DT3NnLVc1WW5PWFpQZmU3clZDVHZDR3RDeGw3WHVWQmVGLWZFWmQ2amt6cmlZZFIyd1dUN0RRd1Q2SEo3T2UxR29IQ0tSNUNCVk9PREZqTUE4ckoweENpS1F2QkVJb3Fjd0h4dUpvUkZMSG9UMzAwXzdCbWtSZw?oc=5","date":"2020-05-28","type":"pipeline","source":"Pharmacy Times","summary":"Value Based Contracts for Specialty Pharmacy - Pharmacy Times","headline":"Value Based Contracts for Specialty Pharmacy","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}